Psoriasis light therapy trial pulled before it began
NCT ID NCT03507946
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study aimed to test a new LED light device for treating mild to moderate plaque psoriasis. Participants would have treated one plaque at home with the device for 15 minutes daily, five days a week for 12 weeks, while leaving another plaque untreated for comparison. However, the trial was withdrawn before enrolling any volunteers, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- LED light device (460nm, 633nm, 830nm)
- What this could lead to
- If it had worked, this could point toward a convenient at-home light therapy for easing psoriasis plaques.
- What could go wrong
- The trial was withdrawn before any participants were enrolled, so no results are available. It is unclear if the device would have been effective or safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Expected to start
-
Jan 2023
An estimate. Start dates often move.
- Expected to finish
-
Jun 2024
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Healthy male \& females; 18 to 65 years of age with mild to moderate psoriasis ≤10 PASI according to the Psoriasis Area Severity Index. Plaques comparable in terms of size, duration and severity and where possible on comparable body areas according to the localized psoriasis severity index (LPSI). Fitzpatrick, I-V photo type skin types. Written informed consent is given. Volunteers agree NOT to use any over the counter or prescriptive psoriasis treatments during the study period unless specifically advised by the research staff. Exclusion Criteria: Volunteers who suffer from Erythrodermic, exfoliative or pustular psoriasis. Volunteers who suffer from a systemic photosensitive disorder such as Lupus erythematosus, photosensitive eczema or Albinism. Volunteers who suffer from genetic deficiencies that increase susceptibility to dermatologic cancer such as Xeroderma pigmentosum. Volunteers who suffer from diffuse actinic damage of the skin. Volunteers who suffer from localised fungal or bacterial skin infections in or around the treatment area. Volunteers currently taking (or a history of taking) medication listed in Photosensitive drug list in instructions for use. Subjects who have any known allergies to the ingredients in the emollient used in the study. Volunteers with known malignancy and or undergoing chemotherapy, radiotherapy or high doses of corticosteroids. Volunteer suffers from keloid scars, or birthmarks in the treatment area. Females who are pregnant, breastfeeding or who wish to become pregnant during the study period. Enrolled in another clinical trial during the same study period. The volunteer has a planned hospital admission and/or surgical procedure for an illness or disease which existed before enrolment into the clinical trial and which may interfere with the course or outcome of the study. The volunteer has a medical or psychological condition(s) associated with a risk of poor protocol compliance (e.g. alcoholism or drug abuse). A volunteer is undergoing or is likely to undergo other treatments.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Psoriasis vulgaris are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new oral drug tame psoriasis? early safety trial begins
- Can an ancient herbal mix tame psoriasis flares?
- Small study to uncover how psoriasis drug tames the immune system
- Psoriasis drug trial aims to calm overactive immune cells
- Diabetes drug cream shows promise for psoriasis in new trial
- Blood test may end guesswork in psoriasis dosing